1001 related articles for article (PubMed ID: 28823558)
1. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
2. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.
Sun J; He X; Zhu Y; Ding Z; Dong H; Feng Y; Du J; Wang H; Wu X; Zhang L; Yu X; Lin A; McDonald T; Zhao D; Wu H; Hua WK; Zhang B; Feng L; Tohyama K; Bhatia R; Oberdoerffer P; Chung YJ; Aplan PD; Boultwood J; Pellagatti A; Khaled S; Kortylewski M; Pichiorri F; Kuo YH; Carlesso N; Marcucci G; Jin H; Li L
Cell Stem Cell; 2018 Sep; 23(3):355-369.e9. PubMed ID: 30146412
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation.
Bai J; Yokomizo-Nakano T; Kubota S; Sun Y; Kanai A; Iimori M; Harada H; Iwama A; Sashida G
Oncogene; 2021 Feb; 40(8):1531-1541. PubMed ID: 33452460
[TBL] [Abstract][Full Text] [Related]
5. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
6. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.
Song SJ; Ito K; Ala U; Kats L; Webster K; Sun SM; Jongen-Lavrencic M; Manova-Todorova K; Teruya-Feldstein J; Avigan DE; Delwel R; Pandolfi PP
Cell Stem Cell; 2013 Jul; 13(1):87-101. PubMed ID: 23827711
[TBL] [Abstract][Full Text] [Related]
8. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia.
Chen L; Fan X; Zhu J; Chen X; Liu Y; Zhou H
RNA Biol; 2020 Jun; 17(6):784-793. PubMed ID: 32174258
[TBL] [Abstract][Full Text] [Related]
10. Tet2 restrains inflammatory gene expression in macrophages.
Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
[TBL] [Abstract][Full Text] [Related]
11. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
[TBL] [Abstract][Full Text] [Related]
12. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
[TBL] [Abstract][Full Text] [Related]
13. TET2 deficiency leads to stem cell factor-dependent clonal expansion of dysfunctional erythroid progenitors.
Qu X; Zhang S; Wang S; Wang Y; Li W; Huang Y; Zhao H; Wu X; An C; Guo X; Hale J; Li J; Hillyer CD; Mohandas N; Liu J; Yazdanbakhsh K; Vinchi F; Chen L; Kang Q; An X
Blood; 2018 Nov; 132(22):2406-2417. PubMed ID: 30254129
[TBL] [Abstract][Full Text] [Related]
14. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK
Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816
[No Abstract] [Full Text] [Related]
15. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
[TBL] [Abstract][Full Text] [Related]
16. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract][Full Text] [Related]
17. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
18. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
19. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
[TBL] [Abstract][Full Text] [Related]
20. [TET2 as a gatekeeper for hematologic malignancies].
Muto H; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
